$383 Million is the total value of Ghost Tree Capital, LLC's 39 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 63.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| KALV | Sell | KALVISTA PHARMACEUTICALS INC | $11,448,000 | +36.4% | 400,000 | -5.9% | 2.99% | -1.8% |
| MRTX | Sell | MIRATI THERAPEUTICS INC | $10,995,000 | -35.2% | 150,000 | -62.5% | 2.87% | -53.3% |
| ANAB | Sell | ANAPTYSBIO INC | $8,401,000 | -5.9% | 115,000 | -17.9% | 2.20% | -32.3% |
| BOLD | Sell | AUDENTES THERAPEUTICS INC | $6,829,000 | +6.8% | 175,000 | -41.7% | 1.78% | -23.1% |
| TCDA | Sell | TRICIDA INC | $5,793,000 | -1.7% | 150,000 | -40.0% | 1.51% | -29.3% |
| OBSV | Sell | OBSEVA SA | $2,558,000 | -63.3% | 200,000 | -63.6% | 0.67% | -73.6% |
| GNCA | Sell | GENOCEA BIOSCIENCES INC | $1,180,000 | +16.7% | 2,000,000 | -43.3% | 0.31% | -16.1% |
| CBIO | Sell | CATALYST BIOSCIENCES INC | $811,000 | -48.6% | 100,000 | -50.0% | 0.21% | -63.0% |
| MDGL | Exit | MADRIGAL PHARMACEUTICALS INC | $0 | – | -900 | -100.0% | -0.04% | – |
| MOTS | Exit | MOTUS GI HLDGS INC | $0 | – | -100,000 | -100.0% | -0.11% | – |
| PTI | Exit | PROTEOSTASIS THERAPEUTICS IN | $0 | – | -190,000 | -100.0% | -0.22% | – |
| ITCI | Exit | INTRA CELLULAR THERAPIES INCcall | $0 | – | -79,400 | -100.0% | -0.33% | – |
| UROV | Exit | UROVANT SCIENCES LTD | $0 | – | -300,000 | -100.0% | -0.72% | – |
| SAGE | Exit | SAGE THERAPEUTICS INCcall | $0 | – | -30,000 | -100.0% | -1.04% | – |
| GBT | Exit | GLOBAL BLOOD THERAPEUTICS INput | $0 | – | -85,000 | -100.0% | -1.27% | – |
| BDSI | Exit | BIODELIVERY SCIENCES INTL IN | $0 | – | -1,000,000 | -100.0% | -1.34% | – |
| ZFGN | Exit | ZAFGEN INC | $0 | – | -750,000 | -100.0% | -1.35% | – |
| SRPT | Exit | SAREPTA THERAPEUTICS INC | $0 | – | -70,000 | -100.0% | -2.77% | – |
| BHVN | Exit | BIOHAVEN PHARMACTL HLDG CO L | $0 | – | -275,000 | -100.0% | -3.69% | – |
| IMMU | Exit | IMMUNOMEDICS INCput | $0 | – | -800,000 | -100.0% | -4.14% | – |
| DRNA | Exit | DICERNA PHARMACEUTICALS INC | $0 | – | -1,250,000 | -100.0% | -4.85% | – |
| XBI | Exit | SPDR SERIES TRUSTcall | $0 | – | -750,000 | -100.0% | -19.53% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2020-04-09
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MIRATI THERAPEUTICS INC | 30 | Q3 2023 | 7.3% |
| ASCENDIS PHARMA A/S - ADR | 28 | Q3 2023 | 11.8% |
| BIOCRYST PHARMACEUTICALS INC | 25 | Q2 2023 | 2.4% |
| AMICUS THERAPEUTICS INC | 23 | Q3 2023 | 5.6% |
| SAREPTA THERAPEUTICS INC | 22 | Q3 2023 | 9.1% |
| SPDR SER TR | 20 | Q3 2022 | 16.9% |
| IOVANCE BIOTHERAPEUTICS INC | 18 | Q2 2023 | 5.5% |
| ROCKET PHARMACEUTICALS INC | 18 | Q2 2023 | 6.1% |
| SAGE THERAPEUTICS INC | 18 | Q1 2021 | 4.8% |
| IMMUNOMEDICS INC | 17 | Q2 2020 | 8.7% |
View Ghost Tree Capital, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-16 |
View Ghost Tree Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.